Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Bristol-Myers Squibb & Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) announced the first publication and presentation of results from the KarMMa-3 Phase 3 study…